Novartis Investigative Site

Johor Bahru 80100

2 studies enrolling now · 12 studies all time

What they study most

Acute Heart Failure, Chronic Myelogenous Leukemia, Hidradenitis Suppurativa, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Plaque Psoriasis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Primary Immune Thrombocytopenia, Primary Immune Thrombocytopenia (ITP), Primary Myelofibrosis (PMF), Primary Prevention of Atherosclerotic Cardiovascular Disease, Warm Autoimmune Hemolytic Anemia (wAIHA)

Studies at this site

• A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) — Recruiting now
• Asciminib Roll-over Study — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia — Running, not enrolling
• A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids — Running, not enrolling
• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) — Running, not enrolling
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies — Running, not enrolling
• Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa — Running, not enrolling
• Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) — Completed
• Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis — Completed
• Global Non-interventional Heart Failure Disease Registry — Stopped early